Effect of IFN-β on human glioma cell lines with temozolomide resistance

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 139-148

  Yoshino, Atsuo ^a   Ogino, Akiyoshi ^a   Yachi, Kazunari ^a   Ohta, Takashi ^a   Fukushima, Takao ^a   Watanabe, Takao ^a   Katayama, Yoichi ^a   Okamoto, Yutaka ^b   Naruse, Norio ^c   Sano, Emiko ^d  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Toray Medical Company   (Japan)

^c Proteios Research Inc   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Human interferon ; Malignant glioma; Methylation; MGMT; Temozolomide

Indexed keywords

BETA INTERFERON; DNA; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MEDICAL RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTERFERON-BETA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 67649419005     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000322     Document Type: Article

References (69)

1. Bower M, Newlands ES, Bleehen NM, et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488, 1997.
2. Paulsen F, Hoffmann W, Becker G, et al: Chemotherapy in the treatment of recurrent glioblastoma multiforme: isofamide versus temozolomide. J Cancer Res Clin Oncol 125: 411-418, 1999.
3. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000.
4. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771, 1999.
5. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
6. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL and Slack JA: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051, 1994.
7. D'Atri S, Tentori L, Lacal PM, et al: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341, 1998.
8. 2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61: 1957-1963, 2001.
9. Ludlum DB: DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 233: 117-126, 1990.
10. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51: 167-223, 1995.
11. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002.
12. Kaina B and Christmann M: DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40: 354-367, 2002.
13. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.
14. Belanich M, Pastor M, Randall T, et al: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56: 783-788, 1996.
15. 6-methylguanine-DNA methyltransferase to resistance to 1,3-bis-(2-cholorethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol Carcinog 13: 81-88, 1995.
16. 6-methylguanine-DNA methyltransferase to monofunctional alkylating agent resistance in human tumor-derived cell lines. Mol Carcinog 13: 70-80, 1995.
17. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5: 807-814, 1999.
18. 6-methylguanine-DNA methyltransferase gene expression in gliomas by quantitative real-time RT-PCR and clinical response to nitrosoureas. Int J Cancer 103: 67-72, 2003.
19. 6-methylguanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9: 1461-1468, 2003.
20. Crinière E, Kaloshi G, Laigle-Donadey F, et al: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83: 173-179, 2007.
21. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of glioma to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
22. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999.
23. Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874, 2004.
24. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
25. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766-776, 2006.
26. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16: 3310-3315, 1998.
27. Jeuken JW, Cornelissen SJ, Vriezen M, et al: MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065, 2007.
28. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938, 2004.
29. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113: 581-587, 2005.
30. Saito R, Mizuno M, Hatano M, Kumabe T, Yoshimoto T and Yoshida J: Two different mechanisms of apoptosis resistance observed in interferon-β induced apoptosis of human glioma cells. J Neurooncol 67: 273-280, 2004.
31. Vannucchi S, Chiantore MV, Mangino G, Percario ZA, Affabris E, Fiorucci G and Romeo G: Perspective in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type 1 interferons. Curr Med Chem 14: 667-679, 2007.
32. Yoshino A, Katayama Y, Yokoyama T, et al: Therapeutic implication of interferon regulatory factor 1 (IRF-1) and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to IFN-β in glioblastoma cells and prognostic value for DIA. J Neurooncol 74: 249-260, 2005.
33. Yoshida J, Kajita Y, Wakabayashi T and Sugita K: Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumor resection and post-operative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir 127: 55-59, 1994.
34. Wakabayashi T, Hatano N, Kajita Y, et al: Initial and maintenance combination treatment with interferon-β, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 49: 57-62, 2000.
35. Watanabe T, Katayama Y, Yoshino A, Fukaya C and Yamamoto T: Human interferon beta, nimustine hydrochloride and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol 72: 57-62, 2005.
36. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M and Yoshida J: IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65: 7573-7579, 2005.
37. Park JA, Joe YA, Kim TG and Hong YK: Potentiation of antiglioma effect with combined temozolomide and interferon-β. Oncol Rep 16: 1253-1260, 2006.
38. Sidky, YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF and Bryan GT: Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 52: 3528-3533, 1992.
39. Tazulakhova EB, Parshina OV, Guseva TS and Ershov FI: Russian experience in screening, analysis, and clinical application of novel interferon inducers. J Interferon Cytokine Res 21: 65-73, 2001.
40. Mizuno M and Yoshida J: Effect of human interferon β gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol Immunother 47: 227-232, 1998.
41. Mizuno M, Yoshida J, Sugita K, et al: Growth inhibition of glioma cells transfected with the human β-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 50: 7826-7829, 1990.
42. Natsume A, Mizuno M, Ryuke Y and Yoshida J: Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse. Gene Ther 6: 1626-1633, 1999.
43. Natsume A, Tsujimura K, Mizuno M, Takahashi T and Yoshida J: IFN-β gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 47: 117-124, 2000.
44. Osawa H, Mizuno M, Hatano M, et al: Susceptibility to exogenously added interferon-β protein depends on intracellular interferon-β mRNA level in human glioma cells. Cytokine 32: 240-245, 2005.
45. Yagi K, Hayashi Y, Ishida N, Ohbayashi M, Ohishi N, Mizuno M and Yoshida J: Interferon-beta endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: cytocidal effect on glioma transplanted into nude mouse brain. Biochem Mol Biol Int 32: 167-171, 1994.
46. Yoshida J, Mizuno M and Yagi K: Efficient transfection of human interferon-β gene to human glioma cells by means of cationic multilamellar liposomes coupled with a monoclonal antibody J Neurooncol 19: 269-274, 1994.
47. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG island. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
48. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression-free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13: 176-184, 2003.
49. 6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis. Neurol Med Chir 46: 387-394, 2006.
50. 6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-time RT-PCR and clinical response to nitrosoureas. Cell Mol Neurobiol 25: 1067-1071, 2005.
51. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10: 3728-3736, 2004.
52. Higuchi Y and Hashida M: Pharmacokinetics of interferon. Clinic All-Round 52: 2499-2505, 2003.
53. Yamazaki S, Kuramoto K, Matsuo E, Hosoi K, Hara M and Shimizu H: High sensitive enzyme immunoassay of human interferon-β 1. J Immunoassay 10: 57-73, 1989.
54. Yachi K, Watanabe T, Ohta T, et al: Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 33: 469-475, 2008.
55. 6-methylguanine. Mutagenesis 17: 483-487, 2002.
56. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 73: 1049-1052, 1996.
57. Figul M, Söling A, Dong HJ, Chou TC and Rainov NG: Combined effects of temozolomide and ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemother Pharmacol 52: 41-43, 2003.
58. 6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 1: 943-948, 2002.
59. 2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61: 5843-5849, 2001.
60. Mineura K, Yanagisawa T, Watanabe K, Kowada M and Yasui N: Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Int J Cancer 69: 420-425, 1996.
61. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea resistance of human brain tumors. Jpn J Clin Oncol 22: 143-149, 1992.
62. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 58: 1068-1073, 1998.
63. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 23: 1-8, 2004.
64. 6-methylguanine-DNA methyltransferase gene. Cancer Res 57: 3672-3677, 1997.
65. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17: 5612-5619, 1997.
66. Kanzawa T, Bedwell J, Kondo Y, Kondo S and Germano IM: Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99: 1047-1052, 2003.
67. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20: 2277-2283, 2002.
68. Agarwala SS and Kirkwood JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5: 144-151, 2000.
69. Colman H, Berkey BA, Maor MH, et al: Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-β for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol 66: 818-824, 2006.